Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
UCLA, Los Angeles, California University of Florida, Gainesville, Florida University of Iowa Health Care - Department of Neurology, Iowa City, Iowa University of Kansas Medical Center, Department of Neurology, Fairway, Kansas Virginia Commonwealth University, Richmond, Virginia Canada
Centre Intégré Universitaire de Santé et Services Sociaux du Saguenay-Lac-St-Jean, Chicoutimi, Quebec France
Institute of Myology, Paris Italy
The NeMO Clinical Center in Milan, Neurorehabilitation Unit, University of Milan, Milan Fondazione Policlinico A. Gemelli- IRCCS, Rome Spain
Hospital Universitario Donostia, Donostia / San Sebastian United Kingdom
St. George's University Hospital, London